Cargando…

Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement

INTRODUCTION: Treatment strategies to improve clinical outcomes in Takayasu's arteritis (TA) with coronary lesions have ranged from pharmacological therapy to invasive procedures, such as coronary angioplasty, stenting, and surgery. However, the therapeutic strategy for this kind of patient is...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhiwei, Zhang, Hongliang, Wang, Man, Yang, Weixian, Qiao, Shubin, Hu, Fenghuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991006/
https://www.ncbi.nlm.nih.gov/pubmed/33230786
http://dx.doi.org/10.1007/s40744-020-00251-2
_version_ 1783669167953543168
author Huang, Zhiwei
Zhang, Hongliang
Wang, Man
Yang, Weixian
Qiao, Shubin
Hu, Fenghuan
author_facet Huang, Zhiwei
Zhang, Hongliang
Wang, Man
Yang, Weixian
Qiao, Shubin
Hu, Fenghuan
author_sort Huang, Zhiwei
collection PubMed
description INTRODUCTION: Treatment strategies to improve clinical outcomes in Takayasu's arteritis (TA) with coronary lesions have ranged from pharmacological therapy to invasive procedures, such as coronary angioplasty, stenting, and surgery. However, the therapeutic strategy for this kind of patient is still unclear. This study aimed to investigate the clinical characteristics and influence of revascularization versus medical therapy in TA patients with coronary artery involvement. METHODS: We analyzed the medical records of 806 TA patients between January 2008 and December 2019. Clinical features and treatment were analyzed, and patients were categorized into medical treatment and revascularization. Additionally, patients were sorted as percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) based on the strategy of revascularization. RESULTS: Ninety cases with coronary lesions induced by TA were enrolled. Among 90 cases, 39 patients adopted conservative treatment, and 51 patients received revascularization (28 subjects with PCI, 23 participants with CABG). The median follow-up time was 63 (45–91) months. There is no significant difference in cardiovascular death between medical treatment and revascularization (2/39, 5.1% vs. 5/51, 9.8%, P = 0.971). The analysis of subgroup indicated that the mortality caused by cardiovascular disease was also similar in the CABG and PCI (2/28, 7.1% vs. 3/23, 13.0%, P = 0.772). However, the proportion of restenosis is much higher in the PCI compared with that of CABG (39.3%, 8.7%, P = 0.022, respectively). Heart failure is an independent predictor of death in these patients. CONCLUSIONS: There is no significant difference in cardiovascular death between medical treatment and revascularization. The analysis of the subgroup indicated that the mortality caused by cardiovascular disease was also similar in the CABG and PCI, but the restenosis is much higher in the PCI compared with that of CABG. Heart failure is an independent predictor of death in these patients.
format Online
Article
Text
id pubmed-7991006
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-79910062021-04-16 Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement Huang, Zhiwei Zhang, Hongliang Wang, Man Yang, Weixian Qiao, Shubin Hu, Fenghuan Rheumatol Ther Original Research INTRODUCTION: Treatment strategies to improve clinical outcomes in Takayasu's arteritis (TA) with coronary lesions have ranged from pharmacological therapy to invasive procedures, such as coronary angioplasty, stenting, and surgery. However, the therapeutic strategy for this kind of patient is still unclear. This study aimed to investigate the clinical characteristics and influence of revascularization versus medical therapy in TA patients with coronary artery involvement. METHODS: We analyzed the medical records of 806 TA patients between January 2008 and December 2019. Clinical features and treatment were analyzed, and patients were categorized into medical treatment and revascularization. Additionally, patients were sorted as percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) based on the strategy of revascularization. RESULTS: Ninety cases with coronary lesions induced by TA were enrolled. Among 90 cases, 39 patients adopted conservative treatment, and 51 patients received revascularization (28 subjects with PCI, 23 participants with CABG). The median follow-up time was 63 (45–91) months. There is no significant difference in cardiovascular death between medical treatment and revascularization (2/39, 5.1% vs. 5/51, 9.8%, P = 0.971). The analysis of subgroup indicated that the mortality caused by cardiovascular disease was also similar in the CABG and PCI (2/28, 7.1% vs. 3/23, 13.0%, P = 0.772). However, the proportion of restenosis is much higher in the PCI compared with that of CABG (39.3%, 8.7%, P = 0.022, respectively). Heart failure is an independent predictor of death in these patients. CONCLUSIONS: There is no significant difference in cardiovascular death between medical treatment and revascularization. The analysis of the subgroup indicated that the mortality caused by cardiovascular disease was also similar in the CABG and PCI, but the restenosis is much higher in the PCI compared with that of CABG. Heart failure is an independent predictor of death in these patients. Springer Healthcare 2020-11-23 /pmc/articles/PMC7991006/ /pubmed/33230786 http://dx.doi.org/10.1007/s40744-020-00251-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Huang, Zhiwei
Zhang, Hongliang
Wang, Man
Yang, Weixian
Qiao, Shubin
Hu, Fenghuan
Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement
title Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement
title_full Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement
title_fullStr Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement
title_full_unstemmed Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement
title_short Revascularization Versus Medical Therapy in Takayasu's Arteritis Patients with Coronary Artery Involvement
title_sort revascularization versus medical therapy in takayasu's arteritis patients with coronary artery involvement
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991006/
https://www.ncbi.nlm.nih.gov/pubmed/33230786
http://dx.doi.org/10.1007/s40744-020-00251-2
work_keys_str_mv AT huangzhiwei revascularizationversusmedicaltherapyintakayasusarteritispatientswithcoronaryarteryinvolvement
AT zhanghongliang revascularizationversusmedicaltherapyintakayasusarteritispatientswithcoronaryarteryinvolvement
AT wangman revascularizationversusmedicaltherapyintakayasusarteritispatientswithcoronaryarteryinvolvement
AT yangweixian revascularizationversusmedicaltherapyintakayasusarteritispatientswithcoronaryarteryinvolvement
AT qiaoshubin revascularizationversusmedicaltherapyintakayasusarteritispatientswithcoronaryarteryinvolvement
AT hufenghuan revascularizationversusmedicaltherapyintakayasusarteritispatientswithcoronaryarteryinvolvement